This project was run in conjunction with George Church and now it appears when we add the 14 completed there will be 24 individuals who have been sequenced with their entire genomes made public, part of the deal. Complete Genomics has been in and out of the news of late, working to bring down the cost of having a full sequence done for an individual. They do not interpret, they just run the software (algorithms) and present the data and another firm does the interpretations. Their goal, and I don’t know if we have reached this point yet, was to have an entire sequence available for 5K. BD
From a prior post:
“This is a nice grouping of videos recently uploaded, first off George Church, swimming, and talking. I do like that swimming pool, but back on course, the 3 videos below talk to George Church and two of the other participants Rosalyn Gill-Garrison and Dr. John Halamka. The interviews and film footage are very well done and have the same 2 minute introduction, so fast forward the last 2 if you don’t want to see the same intro again. By the way, there’s an effort going on to recruit the next wave and you can read more at the link below.”
Complete Genomics has sequenced, analyzed and delivered 14 human genomes since March 2009. Considering that fewer than 20 genomes have been sequenced and published to date, this represents a significant advance for medical research.
Complete Genomics’ current customers are using human genome sequencing technology to conduct small pilot projects, each comprised of five to 10 genomes. These customers represent a mix of academic research institutions and biopharmaceutical companies and include Pfizer, the Flanders Institute for Biotechnology (VIB), Duke University, Brigham & Women’s Hospital, the HudsonAlpha Institute for Biotechnology, and the Ontario Institute for Cancer Research in addition to the Institute for Systems Biology and Broad Institute of MIT and Harvard. These customers send DNA samples to the company and receive their requested genome data. Because they do not need to purchase instruments or reagents, it greatly reduces the cost and complexity of sequencing complete human genomes.
The pilot projects are being used to evaluate the technology and also to conduct small-scale disease studies to investigate conditions as diverse as cancer (breast, lung, colorectal and melanoma), HIV and schizophrenia.
Dr. George M. Church, professor of genetics at Harvard Medical School, director of the Center for Computational Genetics, and member of Complete Genomics’ Scientific Advisory Board, described his experience: “As part of the Personal Genome Project, we have had a single human genome sequenced by Complete Genomics. We have cross-validated Complete Genomics’ resulting data set, including a list of variants, to gauge its technical accuracy. I am pleased with the quality of the data provided. Complete Genomics’ technology can clearly deliver high-quality genomic data, which compare favorably with other published results, and at a low cost. I look forward to continuing to work with the company as it scales up the process to sequence thousands of genomes next year.”